TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31186395
Drug: DSA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSA treatment group
Study: 12910523
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and paclitaxel (C/P) for 4 cycles (AUC of 6 for carboplatin and 200 mg/m2 for paclitaxel every 21 days)
Study: 9259219
Drug: Short cognitive
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short cognitive behavioural group therapy programme focused on patient education and stress relaxation.
Study: 8318322
Drug: Extradural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extradural clonidine 450 micrograms plus oral yohimbine 16 mg
Study: 26846934
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (2 sessions per week for 6 weeks)
Study: 26846934
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (hip arthroscopy and physical therapy)
Study: 16639677
Drug: Heparin-coated ECC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated ECC circuits (group A)
Study: 14583417
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 alfalfa capsules per day)
Study: 14583417
Drug: Low-dose kelp
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose kelp (2 kelp capsules and 2 alfalfa capsules per day)
Study: 14583417
Drug: High-dose kelp
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose kelp (4 kelp capsules per day)
Study: 10981244
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors in hypertensive patients
Study: 10981244
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors in normotensive patients
Study: 10981244
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors usage over time
Study: 10981244
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors in patients with adverse renal outcomes
Study: 7643882
Drug: Heparin (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (10,000 IU bolus followed by intravenous infusion for 24 hours and subcutaneous placebo twice daily for three days)
Study: 7643882
Drug: Intravenous hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hirudin (40 mg bolus followed by intravenous infusion for 24 hours and subcutaneous placebo twice daily for three days)
Study: 7643882
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and subcutaneous hirudin (40 mg bolus followed by intravenous infusion for 24 hours and subcutaneous hirudin twice daily for three days)
Study: 7643882
Drug: Hirudin (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (combined group of intravenous and subcutaneous)
Study: 7643882
Drug: Intravenous hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hirudin
Study: 31124299
Drug: iGlarLixi (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: iGlarLixi (insulin glargine 100 U and lixisenatide)
Study: 20831368
Drug: Locally delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locally delivered doxycycline (8.8% doxycycline gel) as an adjunct to mechanical debridement
Study: 3755608
Drug: CQP201-403 (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQP201-403 (0.025 mg)
Study: 20974324
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of Clopidogrel bisulfate (300 mg on day 1, then 75 mg for 6 days)
Study: 20974324
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of Clopidogrel bisulfate (300 mg on day 1, then 75 mg for 6 days)
Study: 20974324
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of Clopidogrel bisulfate
Study: 20974324
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of Clopidogrel bisulfate
Study: 8777116
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered intravenously over 15 seconds to premedicated children with midazolam
Study: 8777116
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered intravenously over 15 seconds to unpremedicated children
Study: 1497159
Drug: Minidose succinylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minidose succinylcholine (0.1 mg/kg) IV
Study: 1497159
Drug: Pancuronium (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.03 mg/kg) IV
Study: 22587345
Drug: Glimepiride 1-2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1-2 mg
Study: 16043939
Drug: Regimen 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 1: All antihypertensive agents given once a day in the morning
Study: 16043939
Drug: Regimen 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 2: All antihypertensive agents given in the morning, except the CCB which was given at 4:00 pm
Study: 11812685
Drug: Weight-based aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight-based aprotinin dosing schedule
Study: 10520404
Drug: EE/CPA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/CPA (2 mg cyproterone acetate and 0.035 mg ethinyloestradiol)
Study: 1936012
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 40 mg t.i.d.
Study: 1936012
Drug: Molsidomine 8
Normalized name: molsidomine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine 8 mg t.i.d.
Study: 7423136
Drug: Euphyllin retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euphyllin retard (theophylline slow‐releasing coated tablets)
Study: 31819405
Drug: Erdosteine 300
Normalized name: erdosteine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine 300 mg twice daily (n=126)
Study: 17374706
Drug: Oral ethinyl
Normalized name: ethinyl estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ethinyl estradiol (15 microg/d)
Study: 12466695
Drug: Pseudoephedrine (PSE)
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pseudoephedrine (PSE) 120 mg
Study: 9651906
Drug: Pravastatin and
Normalized name: pravastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin and hormone replacement therapy (HRT) (MC group)
Study: 8209274
Drug: Mitomycin/ifosfamide/cisplatin chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin/ifosfamide/cisplatin chemotherapy plus surgery
Study: 3057850
Drug: atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 50 or 100 mg
Study: 3057850
Drug: nadolol 40
Normalized name: nadolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nadolol 40 or 80 mg
Study: 3057850
Drug: both beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: both beta blockers
Study: 24119735
Drug: Entecavir antiviral
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir antiviral treatment (group A)
Study: 19288903
Drug: Acupuncture (encircling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (encircling acupuncture around affected focus, common acupuncture at Hegu (LI 4), Xuehai (SP 10), Fenglong (ST 40), Sanyinjiao (SP 6), venesection and cupping twice a week)
Study: 19288903
Drug: Isotretinoin Capsules
Normalized name: Isotretinoin Capsules
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin Capsules (10 mg, t.i.d.)
Study: 19288903
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (acupuncture and Western medicine)
Study: 12780424
Drug: Advice plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice plus iron supplement (60 mg Fe2+ or 3.6 mg heme iron plus 24 mg Fe2+)
Study: 12780424
Drug: Advice plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice plus iron supplement (3.6 mg heme iron plus 24 mg Fe2+)
Study: 1995766
Drug: High-level IgG
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-level IgG substitution (6 g l-1)
Study: 1995766
Drug: Low-level IgG
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level IgG substitution (3 g l-1)
Study: 24661167
Drug: Alcohol (0.80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.80 g/kg ETOH)
Study: 22159148
Drug: Acute EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute EPO administration (30,000 IU/d for 3 days)
Study: 22159148
Drug: Chronic EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic EPO administration (5000 IU/week for 13 weeks)
Study: 20670234
Drug: mivacurium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.25 mg.kg(‐1) (Group Miva)
Study: 20670234
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% 0.12 ml.kg(‐1) (Group Control)
Study: 17515023
Drug: Acupuncture as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture as an adjunct therapy for IVF
Study: 31004066
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (OAs)
Study: 7635996
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intravenous bolus dose of triazolam
Study: 7635996
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg oral doses of triazolam
Study: 7635996
Drug: 0.20 mg
Normalized name: FENTANYL 10.20 mg in 1 [USP'U] TRANSDERMAL PATCH [Fentanyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.20 mg oral dose of triazolam
Study: 7635996
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg oral dose of triazolam
Study: 7635996
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg oral doses of triazolam
Study: 71604
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine during the first 6 postoperative days
Study: 71604
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine (consecutively treated)
Study: 21084254
Drug: Bone turnover
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone turnover markers (OC, BALP, CTX) before treatment
Study: 21084254
Drug: Bone turnover
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone turnover markers during chemotherapy
Study: 21084254
Drug: Bone turnover
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone turnover markers after therapy
Study: 19032727
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg kg(‐1) dexibuprofen
Study: 19032727
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg kg(‐1) dexibuprofen
Study: 19032727
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg kg(‐1) ibuprofen
Study: 12495164
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care provided by a pharmacist‐managed hypertension clinic
Study: 9803103
Drug: 21 G
Normalized name: Long's Lancets, 21 ga
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 G needle
Study: 9803103
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 21 G and 23 G needles
Study: 9803103
Drug: 21 G
Normalized name: Long's Lancets, 21 ga
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 G needle and 23 G needle
Study: 8572624
Drug: Adjuvant perioperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant perioperative portal liver infusion with fluorouracil, mitomycin and heparin
Study: 8572624
Drug: Adjuvant subclavian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant subclavian intravenous infusion with fluorouracil, mitomycin and heparin
Study: 8572624
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant treatment (Control group)
Study: 2510054
Drug: Cefazedone (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazedone (single-dose prophylactic administration)
Study: 31554943
Drug: Conbercept (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conbercept (0.2 ml)
Study: 31554943
Drug: 5‐fluorouracil (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (0.2 ml)
Study: 24916013
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C plus B vitamins (400 µg folic acid, 2 mg B6, and 10 µg B12)
Study: 24916013
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (50 mg; control group)
Study: 17109336
Drug: Study vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study vaccine at 2 mg (n=5)
Study: 17109336
Drug: Study vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study vaccine at 4 mg (n=20)
Study: 17109336
Drug: Study vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study vaccine at 8 mg (n=15)
Study: 15236274
Drug: Mercaptopurine 75
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mercaptopurine 75 mg/m2 daily
Study: 15236274
Drug: Mercaptopurine 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mercaptopurine 37.5 mg/m2 twice daily
Study: 15236274
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of daily vs twice daily dosing
Study: 12174398
Drug: Community-based health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based health promotion interventions; specific details on dosage and duration not available.
Study: 9401427
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 200 mg caffeine and a short nap
Study: 8185426
Drug: Hydralazine hydrochloride‐isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine hydrochloride‐isosorbide dinitrate combination therapy
Study: 8185426
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (digoxin and diuretic therapy)
Study: 3583499
Drug: Atropine infusion
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine infusion with Method A
Study: 3583499
Drug: Atropine infusion
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine infusion with Method B
Study: 24709463
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin (BLF) 100 mg/day
Study: 24709463
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin (BLF) 100 mg/day + Lactobacillus rhamnosus GG (LGG) 6×10(9) CFU/day
Study: 19043378
Drug: S(+)‐ketamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine (2 mg x kg(‐1) x h(‐1); group A; n=27)
Study: 15530134
Drug: ER-tolterodine with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER-tolterodine with antacid
Study: 15530134
Drug: ER-tolterodine without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ER-tolterodine without antacid
Study: 15530134
Drug: ER-oxybutynin with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER-oxybutynin with antacid
Study: 15530134
Drug: ER-oxybutynin without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ER-oxybutynin without antacid
Study: 7934985
Drug: Glucose alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose alone (GLUC) 4.1 mg/kg/min, n = 8
Study: 7934985
Drug: Glucose with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose with amino acids (TPN) 275 mg N/kg/d, n = 10
Study: 3300045
Drug: Trimethoprim (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (2 X 200 mg for 10 days)
Study: 3300045
Drug: Cotrimoxazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (2 X 160 mg Trimethoprim + 800 mg Sulphamethoxazole for 10 days)
Study: 30098861
Drug: Inhaled milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled milrinone (50 µg/kg)
Study: 30098861
Drug: Inhaled levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled levosimendan (24 µg/kg)
Study: 26563405
Drug: Rehabilitation programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation programme in addition to high-dose methylprednisolone (HDMP)
Study: 26563405
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy alone (HDMP)
Study: 20843662
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional therapy)
Study: 16357191
Drug: Very well
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very well done meat consumption (>10 g/d)
Study: 11241462
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine (IPV) given in different three-dose schedules
Study: 11241462
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine (IPV) given at 18 months
Study: 11241462
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group immunized with the current schedule (first dose at 6 months)
Study: 11241462
Drug: Maternal antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal antibodies present at the time of the first dose
Study: 31133144
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (250 mg twice daily) with topical 3% tranexamic acid (twice daily)
Study: 31133144
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (250 mg twice daily) with topical 20% azelaic acid (daily)
Study: 21868616
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid levels (measured in mg/dl)
Study: 21868616
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid ≤8.2 mg/dl
Study: 8101194
Drug: Terazosin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (5 mg once daily)
Study: 29799827
Drug: HARDL (HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HARDL (HA gel with lidocaine)
Study: 29799827
Drug: HAJUP (HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAJUP (HA gel without lidocaine)
Study: 27115157
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (6 g/day for 8 weeks)
Study: 27115157
Drug: Medium-chain triglycerides
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-chain triglycerides (MCT) oil (6 g/day for 8 weeks)
Study: 25273342
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus chemotherapy (15 mg/kg every 3 weeks or 10 mg/kg every 2 weeks)
Study: 22447880
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow mononuclear cells (BMCs) transendocardial injection (100 million BMCs)
Study: 20131246
Drug: Rituximab (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1,000 mg)
Study: 19115423
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) plus taper
Study: 19115423
Drug: Group support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group support (GS) plus taper
Study: 19115423
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (taper only) plus physician counselling
Study: 12597653
Drug: Bifenthrin 100
Normalized name: Bifenthrin
DrugBank: Bifenthrin (DB15056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifenthrin 100 mg/m2
Study: 12597653
Drug: Bifenthrin 200
Normalized name: Bifenthrin
DrugBank: Bifenthrin (DB15056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifenthrin 200 mg/m2
Study: 12597653
Drug: Bifenthrin 50
Normalized name: Bifenthrin
DrugBank: Bifenthrin (DB15056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifenthrin 50 mg/m2
Study: 12597653
Drug: Bifenthrin 25
Normalized name: Bifenthrin
DrugBank: Bifenthrin (DB15056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifenthrin 25 mg/m2